Coverage Without Uptake: Vertex’s Non-Opioid Journavx Passes 1 Million Scripts, $29M in Sales

The first genuinely new painkiller mechanism in more than twenty years has near-universal insurance coverage in the United States — and revenue that still rounds to a rounding error. Vertex’s bet on non-opioid pain is a commercial experiment the whole industry is watching.

Sources: Vertex Q4/FY2025 and Q1 2026 results (news.vrtx.com; republished at crisprmedicinenews.com); Journavx pricing via Managed Healthcare Executive (managedhealthcareexecutive.com); Casgevy list price widely reported (BioPharma Dive, biopharmadive.com).

In January 2025 the US Food and Drug Administration (FDA) approved Journavx (suzetrigine), the first selective blocker of the NaV1.8 sodium channel — a pain signal that travels along peripheral nerves before it ever reaches the brain. That mechanism matters because it is not an opioid: it does not act on the brain’s reward circuitry and carries no addiction liability. For a country still counting the cost of the opioid epidemic, it was the most important analgesic approval in a generation, and it was positioned exactly that way.

Eighteen months on, the story is not adoption but its absence. By the first quarter of 2026 Journavx had crossed a million prescriptions, secured all three large pharmacy benefit managers (PBMs) — the companies that decide which drugs insurers cover — and reached roughly 240 million covered lives, with 22 state Medicaid programs on board. Washington even cleared a structural barrier: under the NOPAIN Act, a US law taking effect in January 2026, Medicare now pays separately for non-opioid pain treatments rather than bundling them into a hospital fee that discouraged their use. And yet quarterly revenue was just US$29 million. Access, it turns out, is necessary but not sufficient; prescribers reach for the cheap generic opioid they have used for thirty years.

The commercial thesis rests on expansion beyond acute pain into the far larger chronic and neuropathic markets — and there the evidence is mixed. A Phase 2 study of suzetrigine in painful lumbosacral radiculopathy (sciatica-type nerve pain) hit its within-group target but failed to separate from placebo, and Vertex is advancing to Phase 3 with a redesigned trial in diabetic neuropathy. Until that reads out, Journavx is a well-covered drug for short-term pain in search of the blockbuster indication that would justify its price.

A non-addictive painkiller with 240 million covered lives and US$29 million in sales is the clearest evidence yet that coverage does not equal uptake — and that the opioid default is a prescribing habit, not a formulary problem.

For Latin America the relevance is a gap, not a launch. HealthSignals found no public regulatory pathway for Journavx before the Agência Nacional de Vigilância Sanitária (ANVISA) in Brazil or the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in Mexico — an absence worth confirming against each agency’s registry, but a telling one. The starker case is Casgevy, Vertex’s gene therapy for sickle cell disease and beta-thalassemia developed with CRISPR Therapeutics. Sickle cell disease carries a heavy burden across Brazil and the region’s populations of African descent, yet at a US$2.2 million list price and with no regional registration, a functional cure remains a headline rather than an option for the patients who need it most.